deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02086175

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Sponsor: Dana-Farber Cancer Institute

Conditions Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Interventions Imprime PGG Rituximab
Updated 19 times since 2017 Last updated: Apr 5, 2024 Started: Dec 31, 2014 Primary completion: Jul 11, 2019 Completion: Feb 1, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02086175, this PHASE2 trial focuses on Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas and remains completed. Sponsored by Dana-Farber Cancer Institute, it has been updated 19 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Oct 2019 · 5 months · monthly snapshot~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Nov 2021 · 5 months · monthly snapshot~Nov 2021 – ~May 2022 · 6 months · monthly snapshot~May 2022 – ~Oct 2022 · 5 months · monthly snapshot~Oct 2022 – ~Dec 2022 · 2 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~Oct 2023 · 6 months · monthly snapshot~Oct 2023 – ~May 2024 · 7 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Completed PHASE2

  4. Oct 2023 — May 2024 [monthly]

    Completed PHASE2

  5. Apr 2023 — Oct 2023 [monthly]

    Completed PHASE2

▶ Show 14 earlier versions

  1. Jan 2023 — Apr 2023 [monthly]

    Completed PHASE2

  2. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  3. Oct 2022 — Dec 2022 [monthly]

    Completed PHASE2

  4. May 2022 — Oct 2022 [monthly]

    Completed PHASE2

  5. Nov 2021 — May 2022 [monthly]

    Completed PHASE2

  6. Jun 2021 — Nov 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  7. Mar 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Feb 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Completed → Active Not Recruiting

  9. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE2

  10. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  11. May 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  12. Jun 2018 — May 2019 [monthly]

    Recruiting PHASE2

  13. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • HiberCell, Inc.
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations